Wealthsimple US Ltd. cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 39.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,442 shares of the company’s stock after selling 936 shares during the period. Johnson & Johnson makes up 0.1% of Wealthsimple US Ltd.’s portfolio, making the stock its 19th biggest position. Wealthsimple US Ltd.’s holdings in Johnson & Johnson were worth $215,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in the stock. Winslow Evans & Crocker Inc. increased its stake in Johnson & Johnson by 0.3% in the 2nd quarter. Winslow Evans & Crocker Inc. now owns 21,603 shares of the company’s stock worth $3,037,000 after acquiring an additional 69 shares during the last quarter. Lathrop Investment Management Corp boosted its holdings in Johnson & Johnson by 1.4% during the 2nd quarter. Lathrop Investment Management Corp now owns 4,901 shares of the company’s stock valued at $689,000 after acquiring an additional 69 shares during the period. Reik & CO. LLC boosted its holdings in Johnson & Johnson by 0.4% during the 2nd quarter. Reik & CO. LLC now owns 17,727 shares of the company’s stock valued at $2,493,000 after acquiring an additional 70 shares during the period. Delta Investment Management LLC boosted its holdings in Johnson & Johnson by 1.0% during the 2nd quarter. Delta Investment Management LLC now owns 7,406 shares of the company’s stock valued at $1,041,000 after acquiring an additional 71 shares during the period. Finally, IFG Advisory LLC boosted its holdings in Johnson & Johnson by 0.4% during the 2nd quarter. IFG Advisory LLC now owns 16,170 shares of the company’s stock valued at $2,274,000 after acquiring an additional 71 shares during the period. 67.44% of the stock is currently owned by institutional investors.
In related news, EVP Kathryn E. Wengel sold 16,115 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the transaction, the executive vice president now directly owns 66,658 shares of the company’s stock, valued at approximately $10,233,336.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.27% of the company’s stock.
A number of research firms recently issued reports on JNJ. Raymond James restated a “buy” rating on shares of Johnson & Johnson in a report on Friday. Credit Suisse Group upped their target price on Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a report on Wednesday, October 14th. ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, August 3rd. Cantor Fitzgerald upped their target price on Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, October 14th. Finally, Stifel Nicolaus cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, August 19th. One analyst has rated the stock with a sell rating, four have issued a hold rating and ten have issued a buy rating to the stock. Johnson & Johnson presently has a consensus rating of “Buy” and an average price target of $164.93.
JNJ opened at $146.36 on Friday. The firm has a market cap of $385.30 billion, a price-to-earnings ratio of 23.01, a PEG ratio of 3.04 and a beta of 0.69. The company has a current ratio of 1.48, a quick ratio of 1.24 and a debt-to-equity ratio of 0.51. Johnson & Johnson has a 12 month low of $109.16 and a 12 month high of $157.00. The stock has a fifty day moving average price of $145.51 and a 200-day moving average price of $146.57.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Sunday, October 18th. The company reported $2.20 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.98 by $0.22. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The firm had revenue of $21.08 billion during the quarter, compared to analyst estimates of $20.15 billion. During the same period in the previous year, the company posted $2.12 EPS. The business’s revenue for the quarter was up 1.7% compared to the same quarter last year. On average, equities research analysts forecast that Johnson & Johnson will post 7.99 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a yield of 2.76%. The ex-dividend date is Monday, November 23rd. Johnson & Johnson’s dividend payout ratio is currently 46.54%.
Johnson & Johnson Company Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Read More: Forex
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.